Accessibility settings

This paper is in the following e-collection/theme issue:

Cancer Survivorship (451) Innovations and Technology in Cancer Care (679) Clinical Cancer Research (240) Secondary Use of Clinical Data for Research and Surveillance (630) Lung Cancer (113) Cancer Prognosis Models and Machine Learning (137)

Published on in Vol 11 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/64900, first published .
Doctors examining chest x-ray on light box, one pointing and holding tablet

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Authors of this article:

Pierre Heudel1 Author Orcid Image ;   Gema Hernandez2 Author Orcid Image ;   Olivier Denquin2 Author Orcid Image ;   Hugo Crochet1 Author Orcid Image ;   Jean-Yves Blay1 Author Orcid Image
Article Authors Cited by (2) Tweetations (1) Metrics

Journals

  1. Yang X, Kong D, Lai B, Zhang C, Li N. Case Report: Anti-PD-1 therapy as a catalyst for the rapid transformation of a hepatic nodule into HCC: a “soil and seed” paradox in metachronous triple primary malignancies?. Frontiers in Immunology 2026;17 View
  2. Wespiser M, Rochefort P, Gauduchon T, Coste C, Caux C, Ray-Coquard I, Perol M, Blay J, Heudel P. Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception. Cancer Treatment Reviews 2026;149:103200 View